Hexarelin

A hexapeptide ghrelin receptor (GHS-R1a) agonist that also binds CD36 in cardiac tissue, giving it GH-releasing activity plus a distinct, largely GH-independent cardioprotective signaling pathway.

Mechanism of action from published research — how the molecule behaves, not a claim about any product or any human-use effect.

Studied for GH stimulation and, separately, for cardioprotection (reduced cardiomyocyte apoptosis, improved cardiac output) in cardiovascular research.

• Growth hormone supportStudied for how it interacts with the body's own growth-hormone axis in research settings.

In clinical trials (early-phase, discontinued); reached Phase 2 for GH-deficiency diagnosis and cardiac indications but was never marketed.

Where the science stands — an approved drug is not the same as the research-grade material a vendor sells, which is unregulated regardless.

• Independent purity. Look for a third-party COA (Janoshik or MZ) showing a measured purity — not just a number the vendor typed.
• Batch match. The strongest evidence is a certificate for the exact batch you’ll receive, attributed to this vendor — check the cross-verification on the listing.
• Vendor reputation. See how the vendor is talked about in the community before trusting a new name.

Research context only — VialGrade never gives dosing, medical, or human-use guidance.